Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of “Hold” from Analysts
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $24.67.
A number of equities analysts have recently weighed in on AQXP shares. Zacks Investment Research cut Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. ValuEngine cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, BidaskClub cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th.
Aquinox Pharmaceuticals (NASDAQ AQXP) traded down 0.28% on Wednesday, reaching $14.01. 25,133 shares of the company’s stock traded hands. The stock’s market capitalization is $328.74 million. Aquinox Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $19.97. The firm has a 50-day moving average price of $14.24 and a 200-day moving average price of $14.41.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.59). On average, analysts predict that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/11/aquinox-pharmaceuticals-inc-aqxp-receives-consensus-recommendation-of-hold-from-analysts.html.
A number of institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. boosted its holdings in Aquinox Pharmaceuticals by 4.7% during the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after acquiring an additional 939 shares during the period. Northern Trust Corp boosted its holdings in Aquinox Pharmaceuticals by 3.3% during the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after acquiring an additional 2,691 shares during the period. Bank of New York Mellon Corp boosted its holdings in Aquinox Pharmaceuticals by 16.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after acquiring an additional 3,299 shares during the period. Archon Partners LLC boosted its holdings in Aquinox Pharmaceuticals by 44.0% during the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after acquiring an additional 5,500 shares during the period. Finally, Investment Centers of America Inc. purchased a new position in Aquinox Pharmaceuticals during the 1st quarter valued at about $172,000. Institutional investors own 95.15% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.